Drug intelligence / Profile preview

miR-363

Development stage
Preclinical
Lead developer
University of Alabama at Birmingham
Modality
RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous
01

Overview

miR-363 is a microRNA that acts as a tumor suppressor, specifically targeting the Runt-related transcription factor 2 (Runx2). In the context of multiple myeloma (MM), miR-363 is often downregulated, which correlates with the overexpression of Runx2 and subsequent tumor progression and bone metastasis. By binding to Runx2 mRNA, miR-363 suppresses its expression and inhibits downstream signaling pathways such as Akt/β-catenin/survivin. Research indicates that restoring miR-363 levels can reduce MM cell viability, migration, and tumor growth in vivo, suggesting its potential as a therapeutic agent for treating multiple myeloma.

Other names
microRNA-363microRNA363microRNA 363hsa-miR-363hsa-miR363hsa-miR 363
02

Targets

Fibronectin type III domain-containing protein 3B mRNARUNX2SPRYD4 (SPRY domain-containing protein 4)

Beyond the preview

Go deeper on miR-363.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-363.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call